These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 15050096)

  • 1. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation.
    Liuzzo G; Santamaria M; Biasucci LM; Narducci M; Colafrancesco V; Porto A; Brugaletta S; Pinnelli M; Rizzello V; Maseri A; Crea F
    J Am Coll Cardiol; 2007 Jan; 49(2):185-94. PubMed ID: 17222729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inflammatory markers and cytokines in cardiovascular disease].
    Ogiwara F; Takahashi M; Ikeda U
    Rinsho Byori; 2004 Aug; 52(8):686-92. PubMed ID: 15478624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application.
    Blake GJ; Ridker PM
    Ital Heart J; 2001 Nov; 2(11):796-800. PubMed ID: 11770860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Chyrchel M; Dudek D; Bartuś S; Legutko J; Heba G; Dubiel JS
    Kardiol Pol; 2004 Sep; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein. Should it be considered a coronary risk factor?
    Aronow WS
    Geriatrics; 2003 May; 58(5):19-22, 25. PubMed ID: 12756677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [C-reactive protein in cardiovascular diseases].
    Lubas W; Gutkowski K
    Przegl Lek; 2006; 63(7):562-6. PubMed ID: 17203810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D; Banić M; Kardum D
    Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
    Wilson AM; Ryan MC; Boyle AJ
    Int J Cardiol; 2006 Jan; 106(3):291-7. PubMed ID: 16337036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
    Arnaud C; Burger F; Steffens S; Veillard NR; Nguyen TH; Trono D; Mach F
    Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1231-6. PubMed ID: 15790934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
    Koenig W
    Ital Heart J; 2001 Mar; 2(3):157-63. PubMed ID: 11305526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein: a novel marker of cardiovascular risk.
    Shah SH; Newby LK
    Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.